支气管肺泡灌洗结合糖皮质激素治疗急性加重期特发性肺纤维化患者的效果及安全性

doi:10.3760/cma.j.issn.1007-1245.2023.16.016

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (16): 2289-2292.DOI: 10.3760/cma.j.issn.1007-1245.2023.16.016

支气管肺泡灌洗结合糖皮质激素治疗急性加重期特发性肺纤维化患者的效果及安全性

张萌李威徐敬敬

驻马店市中心医院RICU，驻马店　463000

收稿日期:2023-03-23 出版日期:2023-08-15 发布日期:2023-08-29
通讯作者: 张萌，Email：zhangmengwe21@163.com
基金资助:
河南省科技攻关项目（SBGJ202103053）

Efficacy and safety of bronchoalveolar lavage combined with glucocorticoids in treatment of patients with acute exacerbation of idiopathic pulmonary fibrosis

Zhang Meng, Li Wei, Xu Jingjing

RICU, Zhumadian Central Hospital, Zhumadian 463000, China

Received:2023-03-23 Online:2023-08-15 Published:2023-08-29
Contact: Zhang Meng, Email: zhangmengwe21@163.com
Supported by:
Problem-tackling Project of Science and Technology in Henan (SBGJ202103053)

摘要/Abstract

摘要：

目的　观察支气管肺泡灌洗（BAL）结合糖皮质激素治疗急性加重期特发性肺纤维化（IPF）患者的效果及安全性。方法　选择2021年1月至2022年10月驻马店市中心医院收治的123例急性加重期IPF患者进行随机对照试验。采用抽签法将患者分为对照组（61例）和观察组（62例）。对照组男40例，女21例，年龄（60.45±5.25）岁；观察组男42例，女20例，年龄（61.25±5.36）岁。对照组糖皮质激素治疗，观察组BAL结合糖皮质激素治疗。比较两组患者治疗前后肺纤维化改善情况及预后情况。采用t检验和χ²检验。结果　治疗前，两组肺纤维化评分（Ashcroft）、肺纤维化指标差异均无统计学意义（均P>0.05）。治疗3、7、14 d后，观察组Ashcroft评分均低于对照组［（4.45±1.22）分比（5.33±1.25）分、（3.05±0.27）分比（4.24±1.33）分、（2.28±0.47）分比（3.31±0.46）分，均P<0.05］。治疗后，观察组血红素氧合酶-1（HO-1）、细胞间黏附分子-1（ICAM-1）、透明质酸（HA）水平均低于对照组［（45.25±10.37）ng/L比（51.72±10.36）ng/L、（64.48±10.45）ng/L比（70.44±10.28）ng/L、（9.25±2.36）μg/L比（12.75±3.44）μg/L，均P<0.05］。观察组不良事件发生率低于对照组［9.68%（6/62）比21.31%（13/61），P<0.05］。观察组治疗相关并发症发生率略高于对照组［8.06%（5/62）比6.56%（4/61），P>0.05］。结论　采用BAL配合糖皮质激素治疗急性加重期IPF对改善患者肺纤维化病情及预后有重要意义，且未明显增加并发症发生风险，安全性高。

关键词:

特发性肺纤维化, 支气管肺泡灌洗, 糖皮质激素, 预后

Abstract:

Objective　To observe the efficacy and safety of bronchoalveolar lavage (BAL) combined with glucocorticoids in the treatment of patients with acute exacerbation of idiopathic pulmonary fibrosis (IPF). Methods　One hundred and twenty-three patients with acute exacerbation of IPF who received treatment at Zhumadian Central Hospital from January 2021 to October 2022 were selected for the randomized controlled trial. The patients were divided a control group (61 cases) and an observation group (62 cases) by lottery. There were 40 males and 21 females in the control group; they were (60.45±5.25) years old. There were 42 males and 20 females in the observation group; they were (61.25±5.36) years old. The control group took glucocorticoids, and the observation group BAL and glucocorticoids. The improvement and prognosis of pulmonary fibrosis were compared between the two groups before and after the treatment. t and χ² tests were applied. Results　Before the treatment, there were no statistical differences in the pulmonary fibrosis score (Ashcroft) and pulmonary fibrosis indicators between the two groups (all P>0.05). Three, seven, and fourteen days after the treatment, the Ashcroft scores in the observation group were lower than those in the control group [(4.45±1.22) vs. (5.33±1.25), (3.05±0.27) vs. (4.24±1.33), and (2.28±0.47) vs. (3.31±0.46); all P<0.05]. After the treatment, the levels of heme oxygenase-1 (HO-1), intercellular adhesion molecule-1 (ICAM-1), and hyaluronic acid (HA) in the observation group were lower than those in the control group [(45.25±10.37) ng/L vs. (51.72±10.36) ng/L, (64.48±10.45) ng/L vs. (70.44±10.28) ng/L, and (9.25±2.36) μg/L vs. (12.75±3.44) μg/L; all P<0.05]. The incidence of adverse events in the observation group was lower than that in the control group [9.68% (6/62) vs. 21.31% (13/61); P<0.05]. The incidence of treatment related complications in the observation group was slightly higher than that in the control group [8.06% (5/62) vs. 6.56% (4/61); P>0.05]. Conclusion　BAL combined with glucocorticoids in the treatment of patients with acute exacerbation of IPF is of great significance in improving their conditions and prognosis, does not significantly increase the risk of complications, and has high safety.

Key words:

Idiopathic pulmonary fibrosis, Bronchoalveolar lavage, Glucocorticoids, Prognosis

张萌李威徐敬敬.

支气管肺泡灌洗结合糖皮质激素治疗急性加重期特发性肺纤维化患者的效果及安全性 [J]. 国际医药卫生导报, 2023, 29(16): 2289-2292.

Zhang Meng, Li Wei, Xu Jingjing.

Efficacy and safety of bronchoalveolar lavage combined with glucocorticoids in treatment of patients with acute exacerbation of idiopathic pulmonary fibrosis [J]. International Medicine and Health Guidance News, 2023, 29(16): 2289-2292.

参考文献

[1] 王喜莲. 大剂量N-乙酰半胱氨酸对特发性肺间质纤维化患者肺纤维化及氧化应激的影响[J]. 国际医药卫生导报,2019,25(16):2783-2786. DOI:10.3760/cma.j.issn.1007- 1245. 2019.16.056.
[2] Luppi F, Kalluri M, Faverio P, et al. Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management [J]. Respir Res, 2021, 22(1):109. DOI: 10.1186/s12931-021- 01711-1.
[3] 熊旭东. 糖皮质激素治疗特发性肺纤维化急性加重的研究进展[J]. 安徽医药,2020,24(3):425-428. DOI:10.3969/j.issn.1009-6469.2020.03.001.
[4] 戴勇,曾崎冈,段晨霞,等. 小剂量糖皮质激素、N-乙酰半胱氨酸联合有氧抗阻肺康复疗法治疗特发性肺纤维化的临床疗效及对相关炎症介质表达的影响[J]. 实用医学杂志,2020,36(20):2856-2860. DOI:10.3969/j.issn.1006-5725. 2020.20.023.
[5] Hogea SP, Tudorache E, Pescaru C, et al. Bronchoalveolar lavage: role in the evaluation of pulmonary interstitial disease [J]. Expert Rev Respir Med, 2020,14(11):1117-1130. DOI: 10.1080/17476348.2020.1806063.
[6] 周瑛,李惠萍. 2018ATS/ERS/JRS/ALAT特发性肺纤维化诊断指南解读[J]. 同济大学学报(医学版),2018,39(6):30-33. DOI:10.16118/j.1008-0392.2018.06.007.
[7] 徐勇胜,郭伟. 肺功能检查与肺间质疾病[J]. 中华实用儿科临床杂志,2019,34(16):1204-1207. DOI:10.3760/cma.j.issn.2095-428X.2019.16.002.
[8] Zhu X, Yuan S, Zheng X, et al. Pre-exposure to aerosolized polyvalent bacterial lysates protects against bleomycin-induced pulmonary fibrosis in mice [J]. Inflammation, 2022, 45(4): 1692-1699. DOI: 10.1007/s10753-022-01653-w.
[9] 李恒妍,贾琦,闫玉琴,等. 特发性肺纤维化患者血清VEGF、TGF-β及IL-8、IL-13水平与肺功能相关性[J]. 分子诊断与治疗杂志,2022,14(3):418-421. DOI:10.3969/j.issn.1674-6929.2022.03.015.
[10] 蔡博,陈娴秋,杨文兰,等. 性别-年龄-肺功能分期与复合生理指数对特发性肺纤维化患者死亡风险的预测价值比较研究[J]. 中国全科医学,2021,24(35):4485-4491. DOI:10.12114/j.issn.1007-9572.2021.00.598.
[11] 薛晓彤,姚凤,张元君. 止咳化痰汤联合糖皮质激素治疗特发性肺间质纤维化疗效分析[J]. 中药药理与临床,2020,36(3):219-223.
[12] 杨晓兰,孙莉,胡永波,等. 特发性肺纤维化患者支气管肺泡灌洗液及血清可溶性细胞粘附分子-1、基质金属蛋白酶-2表达水平及临床意义[J]. 实用医院临床杂志,2022,19(5):178-181. DOI:10.3969/j.issn.1672-6170.2022.05.050.
[13] 罗立,熊沿,王慧,等. 支气管肺泡灌洗液和血清中TGF-βIFN-γ水平与特发性肺纤维化的关系[J]. 河北医学,2021,27(5):762-767. DOI:10.3969/j.issn.1006-6233. 2021.05.013.
[14] 赵红舟,龙杞,刘肇恒,等. 五味子乙素对博来霉素诱导小鼠肺纤维化的干预作用及机制研究[J]. 环球中医药,2021,14(4):556-561. DOI:10.3969/j.issn.1674-1749. 2021.04.002.
[15] 范宇斌,何荣伶,邹丽君,等. 生物标志物在特发性肺纤维化中的临床价值[J]. 南方医科大学学报,2020,40(7):1062-1065. DOI:10.12122/j.issn.1673-4254.2020.07.23.
[16] 白万富,刘玉键,李想,等. 蒙药扫日劳-4味汤对特发性肺纤维化模型大鼠的改善作用及机制初探[J]. 中国药房,2021,32(12):1435-1441. DOI:10.6039/j.issn.1001-0408. 2021.12.05.
[17] 刘雪娇,盛伟利,丁艳艳,等. 特发性肺纤维化急性加重患者预后危险因素及意义[J/CD]. 中华肺部疾病杂志(电子版),2022,15(2):212-214. DOI:10.3877/cma.j.issn.1674-6902. 2022.02.017.
[18] 卢文佳,张晓萍,孙广浩,等. 格拉斯哥及改良格拉斯哥预后评分对特发性肺纤维化急性加重患者预后的意义[J]. 临床肺科杂志,2021,26(9):1326-1331. DOI:10.3969/j.issn. 1009-6663.2021.09.007.

支气管肺泡灌洗结合糖皮质激素治疗急性加重期特发性肺纤维化患者的效果及安全性

Efficacy and safety of bronchoalveolar lavage combined with glucocorticoids in treatment of patients with acute exacerbation of idiopathic pulmonary fibrosis

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	詹泽宇林思恩魏波. 骨肉瘤临床治疗现状与创新疗法研究进展 [J]. 国际医药卫生导报, 2023, 29(9): 1197-1200..
[2]	侯长冉姜京汝花义同. 软骨素聚合因子在乳腺癌中的研究进展 [J]. 国际医药卫生导报, 2023, 29(9): 1201-1204.
[3]	马坤王道斌李树军. 支气管肺泡灌洗液中细胞学对儿童肺部疾病诊治研究进展 [J]. 国际医药卫生导报, 2023, 29(8): 1049-1052.
[4]	张琪赵燕超. 奥美拉唑注射液联合肠内营养支持治疗急性胰腺炎患者的效果 [J]. 国际医药卫生导报, 2023, 29(7): 978-982.
[5]	袁法伟李炳奇. 体外膜肺氧合治疗呼吸衰竭的效果及预后分析 [J]. 国际医药卫生导报, 2023, 29(7): 973-977.
[6]	吴绍惠肖颖秀杨丹晓彭海聪黄晓新. 同型半胱氨酸及胱抑素C对急性脑梗死患者静脉溶栓的疗效影响 [J]. 国际医药卫生导报, 2023, 29(6): 813-817.
[7]	李峰苏艺伟王致. 急性百草枯中毒患者预后影响因素分析 [J]. 国际医药卫生导报, 2023, 29(5): 632-637.
[8]	陈冉冉高晓洁贾实磊梁蝶. 儿童肾病综合征合并急性肾损伤的临床特点及危险因素分析 [J]. 国际医药卫生导报, 2023, 29(5): 675-679.
[9]	宁欣. 中性粒细胞与血小板计数比值对重症肺炎患者预后的预测价值 [J]. 国际医药卫生导报, 2023, 29(4): 545-549.
[10]	张鑫玲甘文云. FTO表达与重症哮喘患者气道炎症和预后的相关性分析 [J]. 国际医药卫生导报, 2023, 29(17): 2398-2401.
[11]	刘璐申潇竹苗磊廖静贤. 高龄社区获得性肺炎患者营养不良及调节性T细胞失衡与预后的相关性研究 [J]. 国际医药卫生导报, 2023, 29(17): 2413-2419.
[12]	丁佰娟张立伟杨慧崔秀娟李南. IGSF9在上皮性卵巢癌中的表达及对卵巢癌细胞转移能力的影响 [J]. 国际医药卫生导报, 2023, 29(16): 2268-2272.
[13]	朱亚明刘合莲. 射血分数降低的急性心力衰竭患者血清钠离子对病情严重程度及预后的评估价值 [J]. 国际医药卫生导报, 2023, 29(16): 2306-2310.
[14]	方文丽. 我国双侧延髓内侧梗死139例临床分析 [J]. 国际医药卫生导报, 2023, 29(15): 2096-2101.
[15]	胡平平周柄宇宋鹏程. 中性粒细胞淋巴细胞比值与IL-10联合检测对COPD患者预后的预测价值 [J]. 国际医药卫生导报, 2023, 29(15): 2184-2188.